Synthesis and dopaminergic activity of 3-(3,4-dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide.
3-(3,4-Dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide was synthesized by a six-step reaction sequence and was evaluated, and compared with apomorphine, for central dopaminergic agonist activity. The compound produced behavioral and biochemical changes characteristic of central dopaminergic stimulation. Administration of 3-(3,4-dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide to rats resulted in the reversal of the reserpine syndrome, stereotypic behavior, contralateral turning following 6-hydroxydopamine lesion of the substantia nigra, a decrease in dopamine turnover, and inhibition of prolactin release. These results indicate that 3-(3,4-dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide is a dopaminergic agonist. However, the compound exhibited a lower potency but a slightly longer duration of action than apomorphine.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D002375:Catalepsy / Q000139:chemically induced; D055598:Chemical Phenomena; D002621:Chemistry; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D011388:Prolactin / Q000097:blood; D011759:Pyrrolidines / Q000138:chemical synthesis* / Q000494:pharmacology; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects*; D013134:Spiperone / Q000378:metabolism
D011759:Pyrrolidines; D011954:Receptors, Dopamine; D013134:Spiperone; D011388:Prolactin; C044233:3-(3,4-dihydroxyphenyl)-1-n-propylpyrrolidine; D001058:Apomorphine; D004298:Dopamine